The ATS International Health Committee, in partnership with the Pulmonary Infections and Tuberculosis and Allergy, Immunology, and Inflammation Assemblies, invite you to join us for a webinar on the prospect of a COVID-19 vaccine.
With global confirmed cases nearing 40 million and over 1 million confirmed fatalities, the novel coronavirus poses one of the greatest threats to population health in the last century. Despite significant efforts to control the spread of the virus, large-scale inoculation programs represent the most powerful tool in overcoming the pandemic. As clinical trials for many vaccine candidates are nearing their end, the discussion must now turn to the economic, ethical, and logistical challenges of bringing a vaccine to market and immunizing a global population. Please join us for perspectives from academia, regulators, industry, and non-profits on the potential impact of a COVID-19 vaccine.
What will be covered:
Presentation #1: The Potential Impact of a COVID-19 Vaccine
Salim S. Abdool Karim, MBBCh, PhD, CAPRISA
Presentation #2: Can we expect to have an effective vaccine?
Jay Kolls, MD, Tulane University
Presentation #3: What does it take to bring a vaccine to market? The Regulatory Landscape
Norman W. Baylor, PhD, Biologics Consulting
Presentation #4: What does it take to bring a vaccine to market? Industry Perspective
Rajeev Venkayya, MD, Takeda Pharmaceuticals
Presentation #5: Taking the Vaccine to the Public - Economic, Ethical, and Community Engagement Considerations
Lois Privor-Dumm, MBA, Johns Hopkins University
Presentation #6: How do you distribute vaccines to a global population?
Katherine O’Brien, MD, MPH, World Health Organization
Roundtable Discussion:
All Participants
Moderators:
David Lewinsohn, MD, PhD, ATS International Health Committee Chair
Samya Nasr, MD, ATS International Health Committee Vice Chair
